Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,377 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Comparator Clear all
Completed Phase 2 Interventional

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

NCT00979251
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir Phosphate, ADS-8902
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation

NCT03047629
View directory record Official record
Conditions
Parkinson's Disease, Constipation
Interventions
ENT-01, Placebo
Drug · Other
Lead sponsor
Enterin Inc.
Industry
Eligibility
30 Years to 86 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

NCT03594227
View directory record Official record
Conditions
Alopecia
Interventions
ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose), Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
25
States / cities
Hot Springs, Arkansas • Rogers, Arkansas • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

NCT05501561
View directory record Official record
Conditions
Influenza, Human
Interventions
Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1, Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1, Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1, Active Comparator: Licensed IIV IIV administered as a single dose intramuscularly on Day 1
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
1,056 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
47
States / cities
Tempe, Arizona • Huntington Beach, California • San Diego, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 20, 2026, 10:13 AM EDT
Not yet recruiting Not applicable Interventional

The Impact of Virtual Doula Services on Birth Outcomes in Rural Communities

NCT07293741
View directory record Official record
Conditions
Birth, Telehealth, Pregnancy, Maternal Health
Interventions
Virtual doula support, Ebook
Other
Lead sponsor
RAND
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 20, 2026, 10:13 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare the Long-term Outcomes After Two Different Anaesthetics

NCT03089905
View directory record Official record
Conditions
Anesthesia, Neurotoxicity, Child Development
Interventions
Sevoflurane, Remifentanil, Dexmedetomidine
Drug
Lead sponsor
Murdoch Childrens Research Institute
Other
Eligibility
Up to 2 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Phase 4 Interventional Results available

Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia

NCT00231894
View directory record Official record
Conditions
Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment
Interventions
Pioglitazone, Life style diet group, Placebo
Drug · Behavioral · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 20, 2026, 10:13 AM EDT
Recruiting No phase listed Observational

Aveir AR Coverage With Evidence Development (CED) Study

NCT06100770
View directory record Official record
Conditions
Cardiac Pacemaker, Arrhythmia, Bradycardia
Interventions
Aveir AR Leadless Pacemaker, Single-chamber atrial transvenous pacemaker
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 10:13 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

NCT04415073
View directory record Official record
Conditions
Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome
Interventions
SNDX-6352, Placebo
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Scottsdale, Arizona • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

NCT02949388
View directory record Official record
Conditions
Chronic Stable Plaque Psoriasis
Interventions
Placebo, 400 mg (200 mg BID), 300 mg (150 mg BID)
Drug
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

NCT01018186
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate/GW642444, Fluticasone propionate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Oxford, Alabama • Huntington Beach, California • Mission Viejo, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

NCT00348283
View directory record Official record
Conditions
Crohn's Disease
Interventions
adalimumab, placebo
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Oct 20, 2026, 10:13 AM EDT
Withdrawn Not applicable Interventional

Enhancing Systems of Care to Improve Hypertension Guideline Implementation

NCT03563872
View directory record Official record
Conditions
Hypertension
Interventions
Intervention, Active Comparator
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 20, 2026, 10:13 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Investigation of Macular Pigment Augmentation on Dark Adaptation

NCT00478439
View directory record Official record
Conditions
Aging, Age-Related Macular Degeneration
Interventions
ZeaVision EyePromise Restore, Multivitamin
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 27, 2010 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Comparison of BLI4700 Bowel Prep Versus an FDA-approved Comparator in Adults Prior to Colonoscopy

NCT03404401
View directory record Official record
Conditions
Colonoscopy
Interventions
BLI4700, Polyethylene glycol bowel preparation
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
23
States / cities
Mobile, Alabama • Tucson, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

COVID-19 iCura SARS-CoV-2 Ag OTC: Clinical Evaluation

NCT05555030
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
iCura COVID-19 Antigen Rapid Home Test, RT-PCR Test
Device · Diagnostic Test
Lead sponsor
New Day Diagnostics
Network
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Anaheim, California • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Metoprolol to Reduce Perioperative Myocardial Injury

NCT03138603
View directory record Official record
Conditions
Heart Diseases
Interventions
Metoprolol Tartrate, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 20, 2026, 10:13 AM EDT
Terminated Phase 3 Interventional

SILtuximab in Viral ARds (SILVAR) Study

NCT04616586
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Lung Diseases, Pneumonia, Respiratory Tract Infections, Respiratory Tract Disease
Interventions
Siltuximab, Normal Saline
Drug · Other
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
12 Years to 65 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Lansing, Michigan • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oxytocin, Emotions and Mirror Neurons

NCT02228031
View directory record Official record
Conditions
Social Cognition, Expressed Emotion
Interventions
Oxytocin, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 20, 2026, 10:13 AM EDT
Active, not recruiting No phase listed Observational

AVEIR DR Coverage With Evidence Development (CED) Study

NCT05932602
View directory record Official record
Conditions
Cardiac Pacemaker, Arrythmia, Bradycardia
Interventions
Aveir DR Leadless Pacemaker System, Dual Chamber Transvenous Pacemaker
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

NCT05393037
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
V116, Placebo, PCV15, PPSV23, PCV15 - Part B
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized-controlled Trial of Post-operative Opiate Quantities After Urogynecologic Surgery

NCT03319277
View directory record Official record
Conditions
Postoperative Pain, Opioid Use
Interventions
Decreased opiate prescription, Routine opiate prescription
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 20, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA

NCT05480228
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
NRD135SE.1, Placebo
Drug · Other
Lead sponsor
James P. Rathmell, MD
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
San Diego, California • Clermont, Florida • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 20, 2026, 10:13 AM EDT
Recruiting Not applicable Interventional

A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Subacute Stroke Survivors

NCT06797154
View directory record Official record
Conditions
Stroke, Stroke Sequelae, Hemiparesis;Poststroke/CVA
Interventions
StrokeWear Behavioral Intervention, Usual Care + Sham
Behavioral · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 20, 2026, 10:13 AM EDT